CancerRop officially restarts as Dx&Vx

CancerRop held an extraordinary general meeting of shareholders on Thursday and decided to change the company name, appoint new board directors, and change some of the articles of incorporation.

During the extraordinary general meeting of shareholders, the company specializing in molecular diagnosis officially changed its name to Dx&Vx. With the name change, the company plans to add a new business area of vaccine to its accumulated infrastructure of the diagnostics business.

With the expanded business are, the company said it aims to fulfill its new goal of protecting the health and life of all mankind through innovative development, production technology, and rapid supply of the latest diagnostic technologies, services, equipment, and therapeutic and preventive drugs in the pandemic era.

DX&VX also appointed Park Sang-tae, CEO of Coree LLC, Lee Yong-koo, vice president of Coree Company, and Lim Jong-yoon, CEO of Hanmi Science, as the new board of directors.

CEO Park is a microbiology researcher who worked at Harvard and Boston University and served as the president of Macrogen America and CEO of Psomagen. As the new CEO of Dx&Vx, Park plans to conduct research and development through open innovation with overseas organizations in general management, diagnostic technology development, and vaccine business.

New executives, such as Vice President Lee and CFO Ahn Chi-woo, will be in charge of business strategy and sales marketing and will improve the management structure of Dx&Vx.

“We will do our best to resume our short-term goal of resuming stock trading by strengthening transparency through corporate renewal and increasing the possibility of sustainable growth,” CEO Park said. “At the same time, the company plans to strengthen its existing business capabilities while promoting strategic new businesses.”

The company has also changed its articles of incorporation to include sales and import and export business for food manufacturing, baby and maternity products, daily necessities, warehousing, logistics management and service, and brokerage business.

“Through such changes in its articles of incorporation, Dx&Vx plans to expand its presence in local and overseas markets, achieve sales growth and turn to profit as soon as possible, and apply for the resumption of its stock trading at an early stage,” a company official said.